Article
Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
Lung cancer (Amsterdam, Netherlands) - 1 May 2021
Luo Yuxi, Wei Jianping, Zhang Jing, Zeng Liangtao, Zeng Zhimin, Liu Anwen
Abstract excerpt
Pulmonary pleomorphic carcinoma (PPC) is a rare and highly malignant subtype of non-small-cell lung cancer (NSCLC), and chemotherapy and radiotherapy are insensitive. Some clinical trials have shown that targetable driver gene mutations, such as EGFR, ALK or BRAF, have rarely been detected in PPC patients, but the incidence of MET exon 14 mutations is more frequent. For these patients with driver gene mutations,...
Topics
- B7-H1 Antigen
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Humans
- Immune Checkpoint Inhibitors
- Indoles
- Lung Neoplasms
- Mutation
- Quinolines